Welcome to our dedicated page for NeOnc Technologies Holdings SEC filings (Ticker: NTHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeOnc Technologies Holdings, Inc. (NTHI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as a Nasdaq-listed issuer focused on central nervous system therapeutics. NeOnc’s filings, including Forms 8‑K and its registration statement on Form S‑1, provide structured insight into its CNS oncology pipeline, corporate transactions and capital structure.
Through recent 8‑K filings, NeOnc has furnished press releases and supporting materials describing updated Phase 1/2a and Phase 2a clinical results for intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma, including radiographic response data, progression-free survival and long-term survival metrics, as well as safety observations. Other 8‑K reports outline U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb development of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors.
Filings also detail material agreements and strategic initiatives, such as a Master Services Agreement with Insights Pharmaceutical Research LLC (IROS) to conduct multi-site clinical trials in the United Arab Emirates, the formation and role of the NuroMENA subsidiary, share exchange transactions, and acquisitions of entities like JandB Holdings, LLC. Additional disclosures cover executive appointments, equity incentive awards, bridge loans, lines of credit and other financing arrangements that support NeOnc’s clinical programs.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand key points from lengthy registration statements, 8‑K event descriptions and related exhibits, helping them interpret how clinical data updates, regulatory decisions, financing structures and governance changes may relate to NTHI’s CNS oncology strategy. Real-time updates from EDGAR ensure that new NeOnc filings are incorporated as they become available, enabling efficient review of the company’s ongoing reporting history.
NeOnc Technologies Holdings, Inc. (NTHI) Form 3 shows that Ishwar K. Puri, identified as a director, filed an initial Section 16 statement related to an
NeOnc Technologies Holdings, Inc. completed a Nasdaq listing in March 2025 and received $11,644,005 from private placement commitments held in escrow until its registration became effective. For the three and six months ended June 30, 2025, the company reported net losses of $5,680,170 and $38,006,186, respectively, and an accumulated deficit of $88,614,631 at June 30, 2025. Shares outstanding were 19,026,776 at June 30, 2025 (18,090,526 at December 31, 2024). The company has material related-party obligations including an accrued advisory fee balance of $5,882,710 and an unpaid litigation settlement payable of $4,000,000. Financing activity includes bridge and promissory note arrangements with original issue discounts and subsequent issuance of promissory notes totaling $4,000,000 as of August 13, 2025. The filing discloses significant accumulated losses, ongoing financing arrangements, and contingent obligations that affect liquidity.
NeOnc Technologies Holdings, Inc. filed an 8-K dated August 18, 2025 reporting a material event: a declaration of non-reliance on previously issued financial statements or a related audit report or completed interim review. The filing is signed by Amir Heshmatpour. The notice is brief and does not include financial tables, earnings data, or details explaining the reasons for the non-reliance statement. The disclosure indicates the company has identified an issue significant enough to withdraw confidence in earlier financial reporting, but the document provides no additional context, corrective actions, timelines, or quantified impacts.
NeOnc Technologies Holdings, Inc. filed a notification that it will be late in submitting its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. The company explains that it needs additional time to complete the final review of its financial statements and related disclosures, specifically regarding non-cash expense charges tied to previously granted restricted stock units.
NeOnc states that the Form 10-Q could not be filed on time without unreasonable effort or expense, and that it is working diligently to finish the report. The company currently expects to file the Form 10-Q within the five-day extension period allowed under Rule 12b-25 of the Securities Exchange Act of 1934.
NeOnc Technologies Holdings, Inc. disclosed two material corporate developments. On August 7, 2025 the company announced it was awarded $2.5 million in NIH STTR grants to advance its drug candidate NEO212 for gliomas and leukemia; the announcement is furnished as Exhibit 99.1. On August 11, 2025 NeOnc announced the official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market; that announcement is furnished as Exhibit 99.2.
The filing notes these press releases are furnished (not deemed "filed") for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings except as expressly stated. The company’s common stock trades as NTHI on Nasdaq and it is identified as an emerging growth company in the filing.
FAQ
What is the current stock price of NeOnc Technologies Holdings (NTHI)?
What is the market cap of NeOnc Technologies Holdings (NTHI)?
